The General Hospital of Mexico (Hospital General de México, HGM) is a hospital in Mexico City, operated by the Secretariat of Health, the federal government department in charge of all social health services in Mexico..
Background. Bisphenol A (BPA) is an endocrine-disrupting chemical with estrogenic properties that affects various tissues. It has been linked to chronic and inflammatory diseases, such as diabetes and metabolic syndrome. Aim. To investigate the obesogenic effects of a single neonatal administration of BPA on obesity and its underlying mechanisms in mice. Methods. We established a neonatal BPA administration model in mice and measured various biochemical parameters. We also analyzed retroperitoneal, mesenteric, and gonadal fat depots using magnetic resonance imaging (MRI). In addition, to provide a translational context, we measured the serum BPA levels in male obese patients. Results. Neonatal BPA administration in mice induced chronic dimorphic obesity and metabolic syndrome only in male mice. These findings were also reproducible in obese male patients, who exhibited higher concentrations of this endocrine-disrupting chemical than their non-obese counterparts. In addition, the results showed that the number of adult male mice was significantly higher in the BPA-treated group compared with the control and vehicle groups. Metabolic and biochemical parameters, such as adipose tissue, cholesterol, triglycerides, and glucose, were also significantly higher in mice that received BPA in the neonatal stage. Conclusion. Single neonatal BPA administration could be used as a novel strategy in the study of obesity. (c) 2026 The Author(s). Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
To review the current literature to understand and analyze the impact of climate change on the spatial dynamics of primary cutaneous coccidioidomycosis. Establishing a causal relationship between climate change and the incidence of primary cutaneous coccidioidomycosis is challenging due to the low number of reported cases. Strong evidence that climate change has altered the epidemiology of pulmonary coccidioidomycosis suggests the same impact on cutaneous infection. Global warming, climate migration, and extreme weather events have led to changes in the spatial dynamics of coccidioidomycosis, both in its pulmonary and primary cutaneous forms, despite being a rare clinical entity. Currently, primary cutaneous coccidioidomycosis should be considered in the differential diagnosis of unusual skin lesions that occur in people living in areas traditionally known to be endemic, as well as in those that are not.
The review summarizes the existing literature on epidemiology, pathogenesis, the clinical spectrum, and manifestations, as well as diagnostic testing and treatment of coccidioidomycosis, and discusses the role of cutaneous manifestations in facilitating early diagnosis. The recent literature emphasizes a variety of clinical manifestations, confirms the added value of combining histopathology/serology, culture, and molecular tests to increase diagnosis accuracy, but also reinforces triazoles as the first-line therapy. Increasing evidence also highlights the host Th1 and Th17 immune response, as well as genomic virulence factors, as key drivers of disease heterogeneity. Early identification of cutaneous signs is crucial for effective treatment, limiting the spread of the disease, and improving outcomes. Severe or refractory disease often requires amphotericin B. Future research should focus on refining rapid diagnostics, risk prediction, and optimized antifungal regimens in both endemic and nonendemic settings. These priorities may guide prospective studies and standardized management pathways to enhance outcomes in diverse populations worldwide.
To examine current evidence regarding the bidirectional communication within the gut–brain–skin axis, the impact of microbiome dysbiosis on immune regulation, and its contribution to the development of inflammatory dermatoses, particularly those linked to Malassezia species. Emerging research supports a dynamic interaction between the intestinal and cutaneous microbiome, demonstrating that alterations in gut microbial composition can influence systemic immune responses and skin inflammation. Dysbiosis has been associated with increased intestinal permeability, systemic inflammatory signaling, and exacerbation of dermatologic conditions such as acne, psoriasis, atopic dermatitis, alopecia areata, and Malassezia-associated disorders. Additionally, psychosocial stress and dietary factors have been shown to modulate this axis. The gut–brain–skin axis represents a complex regulatory network in which microbial homeostasis plays a central role in maintaining immune balance and skin health. Disruption of this equilibrium may contribute to inflammatory and Malassezia-associated skin diseases. A deeper understanding of these interactions may open new avenues for microbiome-targeted therapeutic strategies.
The treatment landscape for Chronic Lymphocytic Leukemia has rapidly evolved from chemoimmunotherapy to highly effective targeted agents. Despite superior efficacy and safety profiles of these novel agents, challenges persist, particularly due to limited head-to-head trials and regional differences in drug availability and molecular testing. This multiregional expert consensus, developed by 13 hematology experts from Latin America, the Middle East and Africa, Asia-Pacific, and Russia using an adapted Delphi approach, provides evidence-informed recommendations for first-line treatment and sequencing tailored to patient risk and real-world resource constraints. The panel agreed on 16 key statements, emphasizing that targeted therapies are preferred for nearly all newly diagnosed patients. Molecular testing for del(17p), TP53 mutation, and IGHV status is recommended for prognosis and treatment planning. High-risk patients (del(17p) and/or TP53 mutation) should preferably receive continuous therapy with second-generation BTK inhibitors (acalabrutinib or zanubrutinib), which are generally preferred over ibrutinib due to safety advantages. Low-risk patients (IGHV-mutated, without del(17p)/TP53) are best suited for time-limited, venetoclax-based regimens. Upon relapse, switching therapeutic classes is recommended: venetoclax after continuous BTKi therapy, and BTKi after fixed-duration venetoclax. Overall, the consensus underscores the importance of individualized, shared decision-making that accounts for molecular risk, comorbidities, and patient preferences, while highlighting global disparities in access to modern CLL therapies.